Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 33 min 18 sec ago

Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product

Wed, 07/01/2015 - 14:52
Technology Pioneer Dr. Vijay Chandru to Continue as Strand's Chairman AURORA, Colo. and BANGALORE, India, July 1, 2015 -- (Healthcare Sales & Marketing Network) -- Strand Life Sciences, a global genomic profiling company that uses next generation seque...
Diagnostics, Oncology, Personnel
Strand Life Sciences, StrandAdvantage, Precision Medicine

Spine Wave Announces the Commercial Launch of the Leva(TM) Interbody Device System

Wed, 07/01/2015 - 14:39
The Leva(TM) Interbody Device System Allows Spine Surgeons to Maximize Bone Graft Volume in a Novel, Expandable Titanium Device SHELTON, CT--(Healthcare Sales & Marketing Network) - Spine Wave, Inc. is committed to the commercialization of high-quality...
Devices, Neurosurgery, Orthopaedic, Product Launch
Spine Wave, StaXx , Leva Interbody Device, spine surgery

Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer

Wed, 07/01/2015 - 14:10
HAMPTON, N.J., July 1, 2015 -- (Healthcare Sales & Marketing Network) -- Celldex Therapeutics, Inc. (CLDX) today announced the promotion of Richard Wright, Ph.D. to Senior Vice President and the newly created position of Chief Commercial Officer. Dr. Wrigh...
Biopharmaceuticals, Oncology, Personnel
Celldex Therapeutics, RINTEGA

First Clinical Cases Performed Using Lombard Medical's Aorfix(TM) Plus Endovascular Stent Graft

Tue, 06/30/2015 - 13:47
Increased Diameter May Allow 10 Percent Increase in Aorfix-Treatable AAA Cases IRVINE, Calif., June 30, 2015 -- (Healthcare Sales & Marketing Network) -- Lombard Medical, Inc. (EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVA...
Devices, Interventional
Lombard Medical, Aorfix Plus, endovascular stent graft, AAA

Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif(R)) in Two Phase III Studies in Multiple Sclerosis

Tue, 06/30/2015 - 13:34
Studies showed superiority on primary and major secondary endpoints in people with relapsing forms of multiple sclerosis Genentech will submit data to the U.S. Food and Drug Administration Phase III study in primary progressive multiple sclerosis ong...
Biopharmaceuticals, Neurology
Genentech, Roche Group, ocrelizumab, Rebif, multiple sclerosis

Mevion Medical Systems Delivers Proton Accelerator to Seidman Cancer Center at University Hospitals

Mon, 06/29/2015 - 15:01
Delivery marks a major milestone in the installation of the first proton therapy system to treat cancer in adults and children in Ohio LITTLETON, Mass.--(Healthcare Sales & Marketing Network)--Mevion Medical Systems is announcing the delivery of the sup...
Devices, Oncology
Mevion Medical Systems, proton therapy, proton beam, radiotherapy

vTv Therapeutics Appoints Rudy Howard as Chief Financial Officer

Mon, 06/29/2015 - 14:56
HIGH POINT, N.C.--(Healthcare Sales & Marketing Network)--vTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today anno...
Biopharmaceuticals, Neurology, Endocrinology, Personnel
vTv Therapeutics, Alzheimer’s disease, diabetes

Aerie Pharmaceuticals Elects Julie McHugh and Michael M. du Toit to the Company’s Board of Directors

Mon, 06/29/2015 - 14:52
IRVINE, Calif.--(Healthcare Sales & Marketing Network)--Aerie Pharmaceuticals, Inc. (AERI) (the "Company"), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the t...
Biopharmaceuticals, Ophthalmology, Personnel
Aerie Pharmaceuticals, Rhopressa, glaucoma

Caldera Medical Announces FDA Clearance for New Generation of Vertessa(R) Lite Polypropylene Mesh for Sacrocolpopexy

Fri, 06/26/2015 - 16:06
Device Maker Continues to Broaden Product Portfolio with a Unique Blue, Lightweight, Flexible-Yet-Strong Mesh for Sacrocolpopexy AGOURA HILLS, Calif.--(Healthcare Sales & Marketing Network)--Caldera Medical, a medical device company leading the developm...
Devices, Product Launch, FDA
Caldera Medical, Vertessa, sacrocolpopexy, Pelvic Organ Prolapse

EYLEA(R) (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion

Fri, 06/26/2015 - 13:58
TARRYTOWN, N.Y., June 26, 2015 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA® (aflibercept) Inj...
Biopharmaceuticals, Ophthalmology, Regulatory
Regeneron Pharmaceuticals, EYLEA, aflibercept, retinal vein occlusion

Spacelabs Reinvents Medical Telemetry with Release of XTR

Thu, 06/25/2015 - 14:56
SNOQUALMIE, Wash.--(Healthcare Sales & Marketing Network)--Spacelabs Healthcare today announced the release of the newest medical telemetry solution on the market – XTR – Xhibit Telemetry. As the original innovators of telemetry with roots in the NASA s...
Devices, Monitoring, Cardiology, Product Launch
Spacelabs, XTR, Xhibit Telemetry, ECG

Pulmatrix Appoints William Duke, Jr., as Chief Financial Officer

Thu, 06/25/2015 - 14:52
LEXINGTON, Mass., June 25, 2015 -- (Healthcare Sales & Marketing Network) -- Pulmatrix, Inc. (PULM) announced today the appointment of William Duke, Jr., as chief financial officer. Mr. Duke previously served as chief financial officer of Valeritas, Inc.,...
Biopharmaceuticals, Drug Delivery, Personnel
Pulmatrix, iSPERSE, cystic fibrosis, chronic obstructive pulmonary disease

Aegerion Pharmaceuticals Appoints Gregory Perry as Chief Financial Officer

Thu, 06/25/2015 - 14:47
CAMBRIDGE, Mass., June 25, 2015 -- (Healthcare Sales & Marketing Network) -- Aegerion Pharmaceuticals, Inc. (AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare d...
Biopharmaceuticals, Personnel
Aegerion Pharmaceuticals

Autonomic Technologies Completes Transatlantic Series D Financing of $43.2M

Thu, 06/25/2015 - 12:10
REDWOOD CITY, CA--(Healthcare Sales & Marketing Network) - Autonomic Technologies®, Inc. (ATI®), developer and manufacturer of Pulsante™, a microstimulator to treat severe headaches, today announced the closing of its series D round of financing fo...
Devices, Neurology, Venture Capital
Autonomic Technologies, Pulsante, microstimulator, Neurostimulation

Medical Device Firm Advanced Cooling Therapy Receives FDA De Novo Clearance for Esophageal Cooling Device to Cool and Warm Patients

Wed, 06/24/2015 - 14:42
CHICAGO--(Healthcare Sales & Marketing Network)--Emerging medical device firm Advanced Cooling Therapy has received a de novo clearance from the US Food and Drug Administration (FDA) to market its first product, the Esophageal Cooling Device (ECD), in the ...
Devices, FDA
Advanced Cooling Therapy, Esophageal Cooling Device

ViraTherapeutics Raises €3.6 Million in the First Closing of a Series A Financing Round to Advance its Novel Oncolytic Virus Platform

Wed, 06/24/2015 - 14:34
Funds will be used to progress ViraTherapeutic's lead product VSV-GP towards clinical proof of concept in patients with solid tumors. INNSBRUCK, Austria, June 24, 2015 -- (Healthcare Sales & Marketing Network) -- ViraTherapeutics GmbH (ViraT), a privat...
Biopharmaceuticals, Oncology, Venture Capital
ViraTherapeutics, Vesicular Stomatitis Virus

Histogenics Corporation Announces Appointment of New Chief Financial Officer

Mon, 06/22/2015 - 16:30
Experienced Financial and Investment Banking Executive Jonathan Lieber to Join Executive Team WALTHAM, Mass., June 22, 2015 -- (Healthcare Sales & Marketing Network) -- Histogenics Corporation (Histogenics) (HSGX), a regenerative medicine company focuse...
Devices, Regenerative Medicine, Orthopaedic, Personnel
Histogenics, NeoCart

Vaxil's Lead Product ImMucin has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma

Mon, 06/22/2015 - 16:24
The FDA approval follows similar recognition for ImMucin from the EMA. This approval demonstrates the FDA's acknowledgement of an existing medical need for treatment of multiple myeloma and ImMucin's potential in treating this type of cancer NESS ZIONA,...
Biopharmaceuticals, Oncology, FDA
Vaxil Bio, ImMucin, multiple myeloma

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong